– Revenue of $1,005.3 Million Slightly Exceeds Guidance –

– Company Reports GAAP Diluted EPS of ($0.08); Non-GAAP Diluted EPS of $1.03 at High End of Guidance –

– Company Maintains Annual Revenue Guidance, Lowers Guidance for GAAP and Non-GAAP EPS –

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal second quarter ended March 29, 2025.

“We delivered on our financial commitments in the second quarter,” said Stephen P. MacMillan, the Company’s Chairman, President and Chief Executive Officer. “Both revenue and non-GAAP EPS finished at the high ends of our guidance ranges, driven by our diagnostics and skeletal businesses, strong profitability, share buybacks and a slightly lower tax rate.”

Recent Highlights

• Revenue of $1,005.3 million decreased (1.2%) for the quarter, or (0.5%) in constant currency. This compares to the guidance range of $995 to $1,005 million that the Company provided in early February.
  • Total organic revenue excluding COVID-19, the divested blood screening and SSI businesses, and the acquired Endomagnetics and Gynesonics businesses decreased (1.4%), or (0.7%) on a constant currency basis.
• GAAP diluted EPS (loss) of ($0.08) for the quarter compared to $0.72 in the prior year period, and declined due to non-cash impairment charges on intangible assets that totaled $220.9 million. Non-GAAP EPS of $1.03 was flat compared to the prior year period, and at the high end of the guidance range of $1.00 to $1.03 that the Company provided in early February.
• Diagnostics revenue of $453.6 million increased 0.8%, or 1.5% in constant currency, primarily driven by higher molecular diagnostics sales, partially offset by lower sales of COVID-19 assays.
  • Excluding COVID-19 revenue, organic diagnostics sales grew 4.5%, or 5.2% on a constant currency basis.
  • Molecular diagnostics revenue increased 1.0%, or 1.7% in constant currency, primarily driven by higher sales of the Company’s BV CV/TV and respiratory assays, as well as Biotheranostics oncology testing.
  • Excluding COVID-19 revenue, molecular diagnostics revenue grew 7.2%, or 7.8% on a constant currency basis.
• Breast Health revenue of $356.2 million decreased (7.4%), or (6.9%) in constant currency, primarily driven by lower sales of mammography capital equipment, partially offset by increased service contract revenue and the inclusion of Endomagnetics revenue.
  • Organic breast health revenue, which excludes sales from the divested SSI and acquired Endomagnetics businesses, decreased (9.7%), or (9.2%) in constant currency.
• Surgical revenue of $162.5 million grew 4.2%, or 5.1% in constant currency, primarily driven by the addition of the acquired Gynesonics business and strong international sales.
  • Organic surgical revenue, which excludes sales from Gynesonics, increased 0.1%, or 1.1% in constant currency.
• The Company repurchased 3.0 million shares for $200 million in the second quarter of fiscal 2025.

Key financial results for the fiscal second quarter are shown in the table below.